Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Condition: Extensive-stage Small Cell Lung Cancer Interventions: Drug: SHR-1316; Drug: Carboplatin; Drug: Etoposide; Drug: Placebo Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials